Interpace Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Interpace Biosciences generated cash of $3,789,000, which is more than the previous year. Cash used in financing activities reached the amount of -$5,032,000 last year. Net change in cash is therefore -$1,330,000.
Cash Flow
| 2014 | -16.37M | -25.36M | 19.21M |
|---|---|---|---|
| 2015 | -19.84M | 26.39M | -21.35M |
| 2016 | -8.94M | 0 | 1.23M |
| 2017 | -15.26M | -29K | 29.88M |
| 2018 | -8.67M | -449K | -9K |
| 2019 | -18.95M | -13.94M | 29.15M |
| 2020 | -14.57M | -1.57M | 16.60M |
| 2021 | -8.71M | -315K | 8.97M |
| 2022 | -7.69M | 6.20M | 3M |
| 2023 | 3.78M | -87K | -5.03M |
IDXG Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.82M | 3.31M | 3.37M | 2.32M | 6.06M | 15.19M | 602K | 8.31M | 23.11M | 45.63M |
Operating activities | ||||||||||
Net income | 802K | -21.95M | -14.94M | -26.45M | -26.72M | -12.18M | -12.21M | -8.33M | -32.99M | -16.07M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.60M | 2.56M | 5.37M | 5.50M | 4.18M | 3.46M | 3.69M | 4.48M | 5.03M | 2.39M |
Stock-based compensation expense | 630K | 1.30M | 1.36M | 2.24M | 1.53M | 0 | 1.27M | 131K | 4.01M | 2.12M |
| Deferred income tax benefit | 630K | 1.30M | 1.36M | 2.24M | 1.53M | 0 | 1.27M | 131K | 4.01M | 2.12M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 49K | -133K | 2.14M | 1.72M | -961K | -3.54M | -1.22M | 4.76M | -5.48M | -3.42M |
Inventories | 0 | 0 | 0 | 0 | -730K | -873K | -3.92M | -4.79M | 3.13M | -493K |
Accounts payable | 489K | -735K | -1.81M | -198K | -835K | 668K | -2.63M | 143K | 1.01M | 786K |
Cash generated by operating activities | 3.78M | -7.69M | -8.71M | -14.57M | -18.95M | -8.67M | -15.26M | -8.94M | -19.84M | -16.37M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -655K |
Investments In Property Plant And Equipment | -470K | -322K | -354K | -1.57M | -131K | -449K | -29K | 0 | -353K | -11.35M |
Acquisitions Net | 383K | 6.52M | 39K | 0 | -13.82M | 0 | 0 | 0 | 26.75M | -13.35M |
Cash generated by investing activities | -87K | 6.20M | -315K | -1.57M | -13.94M | -449K | -29K | 0 | 26.39M | -25.36M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 108K | 335K | 434K | 6.47M | 0 | 23.08M | 1.70M | 451K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -32K | -108K | 0 | -52K | -41K | -9K | -28K | 0 | -208K | -228K |
Repayments of term debt | -2.5M | 3M | -7.92M | -3M | -3.02M | 0 | 0 | -1.33M | 0 | -20M |
Cash used in financing activities | -5.03M | 3M | 8.97M | 16.60M | 29.15M | -9K | 29.88M | 1.23M | -21.35M | 19.21M |
Net Change In Cash | -1.33M | 1.51M | -58K | 451K | -3.74M | -9.13M | 14.59M | -7.70M | -14.80M | -22.52M |
Cash at end of period | 3.49M | 4.82M | 3.31M | 2.77M | 2.32M | 6.06M | 15.19M | 602K | 8.31M | 23.11M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |